Atopic Dermatitis - Drug Pipeline Insight, 2026 100+ Companies And 120+ Therapies Fuel Biologics, TYK2 Inhibitors, Licensing, And Investment Opportunities
Dublin, Oct. 21, 2026 (GLOBE NEWSWIRE) -- "Atopic Dermatitis - Pipeline Insight, 2026" has been added to ResearchAndMarkets.com's offering.
This report provides a comprehensive analysis of the global Atopic Dermatitis pipeline, covering 100+ companies and 120+ investigational drugs across clinical and nonclinical development. It evaluates pipeline products by development stage, product type, route of administration and molecule type, while also examining discontinued and inactive candidates.
Atopic Dermatitis Overview
Atopic Dermatitis (AD), also called eczema, is a chronic inflammatory skin condition that commonly begins in childhood but may occur at any age. It can be recurrent or persistent, with symptoms that include dry skin, intense itching, redness, rash, discoloration and lichenification. Moderate-to-severe Atopic Dermatitis is frequently associated with asthma, allergic rhinitis and food allergies.
The pathophysiology of Atopic Dermatitis is complex and multifactorial, involving skin barrier dysfunction, altered cell-mediated immune responses, IgE-mediated hypersensitivity, genetic susceptibility and environmental factors. Loss-of-function mutations in filaggrin have been associated with severe disease through increased trans-epidermal water loss, altered pH and dehydration. Dysregulation of Th2 and Th1 cytokine activity may also promote immune abnormalities and hypersensitivity. Langerhans cells, inflammatory dendritic epidermal cells and plasmacytoid dendritic cells contribute to disease development.
Diagnosis generally includes a detailed medical history, assessment of allergies and associated conditions, identification of possible triggers, review of previous treatments and examination of affected skin. Blood testing or skin biopsy may be used to exclude alternative causes. Treatment strategies are tailored to disease severity, rash location, individual triggers and therapeutic response. Current options include moisturizers, corticosteroids, calcineurin inhibitors and biologics, with the goals of reducing inflammation and itching, restoring the skin barrier, preventing infection and limiting flare-ups.
Atopic Dermatitis Pipeline Analysis
The report reviews the current Atopic Dermatitis treatment landscape and future market opportunities through detailed clinical and commercial assessments. Pipeline drug profiles include mechanisms of action, clinical studies, regulatory approvals where applicable, development technologies, collaborations, licensing agreements, mergers and acquisitions, funding activities and regulatory designations.
Companies and academic institutions are investigating novel therapeutic approaches intended to address persistent unmet needs in Atopic Dermatitis treatment. The analysis covers Phase III, Phase II, Phase I, Preclinical and Discovery programs, along with relevant clinical trial updates, pharmacological activity, agreements, collaborations and product development news.
Selected Emerging Atopic Dermatitis Drugs
- ICP-332 - Innocare Pharma: ICP-332 is a selective TYK2 inhibitor being developed for T-cell related autoimmune disorders. By targeting a kinase involved in JAK-STAT signaling, the candidate is intended to modulate inflammatory pathways associated with Atopic Dermatitis. It is currently in Phase III clinical development for the condition. APG777 - Apogee Therapeutics: APG777 is a subcutaneous, half-life extended monoclonal antibody targeting IL-13. Phase I findings reported a half-life of 77 days, sustained inhibition of TARC and near-complete inhibition of pSTAT6 for up to 12 months following a single administration. The candidate is in Phase II development for Atopic Dermatitis. Barzolvolimab - Celldex Therapeutics: Barzolvolimab is a humanized monoclonal antibody designed to bind and inhibit KIT, a receptor tyrosine kinase involved in mast cell differentiation, recruitment, survival and activity. The drug is undergoing Phase II clinical evaluation for Atopic Dermatitis. ATI-2138 - Aclaris Therapeutics: ATI-2138 is an investigational oral covalent inhibitor of ITK and JAK3. The candidate is designed to interrupt T cell signaling through combined inhibition of ITK/JAK3 pathways in lymphocytes. It is in Phase II development for Atopic Dermatitis. STAR-0310 - BioCryst Pharmaceuticals: STAR-0310 is a monoclonal antibody designed as an OX40 antagonist. The candidate inhibits a receptor involved in T cell activation and survival, potentially modulating immune responses associated with Atopic Dermatitis. Its profile includes high affinity, strong potency and reduced antibody-dependent cellular cytotoxicity. STAR-0310 is in Phase I clinical development.
Therapeutic Assessment and Development Activity
The Atopic Dermatitis pipeline is segmented by clinical stage, including late-stage Phase III products, mid-stage Phase II candidates, early-stage Phase I programs, Pre-clinical and Discovery assets, and discontinued or inactive candidates. Innocare Pharma is among the companies with an Atopic Dermatitis candidate in Phase III development.
Routes of administration assessed in the report include oral, intravenous, subcutaneous, parenteral and topical delivery. Molecule types include recombinant fusion proteins, small molecules, monoclonal antibodies, peptides, polymers and gene therapies. Products are also classified as Mono, Combination or Mono/Combination therapies.
The report evaluates collaborations, Industry-Industry and Industry-Academia partnerships, licensing transactions, acquisitions, mergers and other strategic activities shaping Atopic Dermatitis research and development. It also examines clinical trial status, emerging technologies, drug classes, regulatory designations, unmet needs and the potential impact of investigational treatments.
Key Companies and Products
Companies covered include Vanda Pharmaceuticals, TechnoDerma Medicines, Asana BioSciences, Artax Biopharma, Corvus Pharmaceuticals, Yuhan, BioVersys, Rubedo Life Sciences, Innocare Pharma, Apogee Therapeutics, Celldex Therapeutics, Aclaris Therapeutics and BioCryst Pharmaceuticals.
Selected pipeline products include Tradipitant, TDM 180935, ASN002, AX 158, Soquelitinib, YH 35324, BV-200, RLS 1496, ICP-332, APG777, Barzolvolimab, ATI-2138 and STAR-0310. Together, these programs illustrate the range of mechanisms, molecule types and development strategies being explored across the Atopic Dermatitis therapeutics market.
Key Topics Covered:
Introduction
Executive Summary
Atopic Dermatitis: Overview
- Introduction Causes Pathophysiology Signs and Symptoms Diagnosis Treatment
Pipeline Therapeutics
- Comparative Analysis
Therapeutic Assessment
- Assessment by Product Type Assessment by Stage and Product Type Assessment by Route of Administration Assessment by Stage and Route of Administration Assessment by Molecule Type Assessment by Stage and Molecule Type
Atopic Dermatitis- Analytical Perspective
Late Stage Products (Phase III)
- Comparative Analysis
ICP-332: Innocare Pharma
- Product Description Research and Development Product Development Activities
Mid Stage Products (Phase II)
- Comparative Analysis
APG777: Apogee Therapeutics
- Product Description Research and Development Product Development Activities
Early Stage Products (Phase I)
- Comparative Analysis
STAR-0310: BioCryst Pharmaceuticals
- Product Description Research and Development Product Development Activities
Preclinical and Discovery Stage Products
- Comparative Analysis
Inactive Products
- Comparative Analysis
Atopic Dermatitis Key Companies
Atopic Dermatitis Key Products
Atopic Dermatitis- Unmet Needs
Atopic Dermatitis- Market Drivers and Barriers
Atopic Dermatitis- Future Perspectives and Conclusion
Atopic Dermatitis Analyst Views
Appendix
List of Tables [12]
List of Figures [12]
A selection of companies mentioned in this report includes, but is not limited to:
- Vanda Pharmaceuticals TechnoDerma Medicines Asana BioSciences Artax Biopharma Corvus Pharmaceuticals Yuhan BioVersys Rubedo Life Sciences Innocare Pharma Apogee Therapeutics Celldex Therapeutics Aclaris Therapeutics BioCryst Pharmaceuticals
For more information about this clinical trials report visit
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Comments
No comment